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Non standard abbreviations 
α2 AR, α2 adrenoceptor; 
aCSF, artificial cerebrospinal fluid; 
CaMKII, calcium/calmodulin-dependent protein kinase; 
Cmpd101, Takeda compound 101; 
CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; 
DAMGO, D-Ala2,N-MePhe4,Gly-ol]-enkephalin; 
DMEM, Dulbecco’s modified Eagles’s medium; 
DNM, dominant negative mutant; 
ECL, enhanced chemiluminescence;  
ERK, extracellular-signal-regulated kinase; 
GIRK channel, G protein-activated potassium channel; 
GRK, G protein-coupled receptor kinase; 
HA, haemagglutin; 
HEK 293 cells, human embryonic kidney 293 cells; 
HRP, horseradish peroxidase; 
JNK, c-Jun N-terminal kinase; 
KO, knock out; 
LC, locus coeruleus;  
MOPr, µ opioid receptor; 
NA, noradrenaline (norepinephrine); 
PDB, pull down buffer; 
PKA, protein kinase A; 
PKC, protein kinase C; 
PMSF, phenylmethanesulfonylfluoride; 
PRK2, protein kinase C related protein kinase; 
PVDF, polyvinylidene fluoride; 
ROCK2, Rho-associated protein kinase 2; 
MOL #98293 
 
4 
 
SDS, sodium dodecyl sulphate; 
SGK1, serum and glucocorticoid regulated kinase (SGK1); 
SST, somatostatin; 
SST2R, somatostatin 2 receptor; 
WGA, wheat germ agglutinin; 
WT, wild type 
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Abstract 
There is ongoing debate about the role of G protein receptor kinases (GRKs) in agonist-
induced desensitization of the µ opioid receptor (MOPr) in brain neurons (see Williams et al., 
2013, Pharmacol Rev 15;223-254). In the present paper we have used a novel, membrane 
permeable, small molecule inhibitor of GRK2 and GRK3, Takeda Compound 101 
(Cmpd101), to study the involvement of GRK2/3 in acute agonist-induced MOPr 
desensitization. We observed that Cmpd101 inhibits the desensitization of the G protein 
activated potassium current (GIRK) evoked by receptor- saturating concentrations of 
methionine enkephalin (Met Enk), D-Ala2,N-MePhe4,Gly-ol]-enkephalin (DAMGO), 
endomorphin-2 and morphine in rat and mouse locus coeruleus (LC) neurons. In LC neurons 
from GRK3 knockout mice Met Enk-induced desensitization was unaffected implying a role 
for GRK2 in MOPr desensitization. Quantitative analysis of the loss of functional MOPrs 
following acute agonist exposure revealed that Cmpd101 only partially reversed MOPr 
desensitization. Inhibition of ERK1/2, PKC, JNK or GRK5 did not inhibit the Cmpd101-
insensitive component of desensitization. In HEK 293 cells Cmpd101 produced almost 
complete inhibition of DAMGO-induced MOPr phosphorylation at Ser375, arrestin 
translocation and MOPr internalization. Our data demonstrate a role for GRK2 (and 
potentially also GRK3) in agonist-induced MOPr desensitization in the LC, but leave open 
the possibility that another, as yet unidentified, mechanism of desensitization also exists. 
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Introduction 
The canonical pathway for homologous G protein-coupled receptor (GPCR) desensitization 
involves agonist activation of the receptor, subsequent G protein activation, G protein-
coupled receptor kinase (GRK) translocation to the plasma membrane, phosphorylation of 
serine and threonine residues primarily on the C-terminal tail of the receptor by GRKs and 
arrestin binding to the phosphorylated receptor (Kelly et al., 2008). While binding of arrestins 
to the receptor prevents further G protein activation (i.e. desensitizes the receptor-G protein-
coupled effector activation pathway) it may also lead to arrestin-mediated signalling and 
receptor internalization, recycling and downregulation (Shenoy & Lefkowitz, 2011). 
 
In LC neurons taken from relatively mature animals DAMGO, a high efficacy MOPr agonist, 
induces substantial homologous MOPr desensitization (Llorente et al., 2012). However, 
despite considerable effort there still remains controversy and confusion around the role of 
GRKs in the rapid desensitization of neuronal µ-opioid receptors (MOPrs) (for extensive 
review, see Williams et al., 2013). Evidence in favour of a role of GRKs in neuronal MOPr 
desensitization by agonists with high intrinsic efficacy is threefold. First DAMGO-induced 
MOPr desensitization in rostral ventromedial medulla neurons was shown to be inhibited by 
intracellular perfusion of a GRK2 inhibitory peptide (Li and Wang, 2001). Second, fentanyl-
induced MOPr desensitization in the hippocampal dentate gyrus was absent in brain slices 
from GRK3 knockout (KO) mice (Terman et al., 2004). Third, overexpression of a GRK2 
dominant negative mutant (DNM) in rat LC neurons reduced DAMGO-induced MOPr 
desensitization (Bailey et al., 2009a). On the other hand two studies have failed to provide 
evidence for any involvement of GRKs in MOPr desensitization. Neither heparin, a low 
affinity GRK inhibitor, nor staurosporine, a non-selective kinase inhibitor, had any effect on 
Met Enk-induced MOPr desensitization in rat LC neurons (Arttamangkul et al., 2012). Also, 
using the GRK2as5 transgenic mouse in which GRK2 has been mutated to allow chemical 
inhibition it was observed that exposure to the inhibitor did not reduce Met Enk-induced 
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desensitization in LC neurons (Quillinan et al., 2011). However, this transgenic knock-
in/chemical inhibition approach would only inhibit GRK2 and not affect GRK3 or other GRKs. 
 
Further complicating the issue, Dang et al., (2009) reported that in rat LC neurons both 
GRKs and ERKs were involved in MOPr desensitization; inhibition of GRK2/3 by intracellular 
dialysis of inhibitory peptides or ERK1/2 with a small molecule ERK1/2 activation inhibitor 
alone did not reduce Met Enk-induced desensitization but with concomitant inhibition of both 
types of kinase desensitization was inhibited. 
 
In LC neurons in vitro morphine, an agonist with lower intrinsic efficacy (McPherson et al., 
2010), induced much less MOPr desensitization than high efficacy opioid agonists (Alvarez 
et al., 2002; Bailey et al., 2003). The level of morphine-induced desensitization could be 
enhanced by concomitant activation of PKC either indirectly by stimulation of Gq-coupled M3 
muscarinic receptors or directly with a phorbol ester (Bailey et al., 2004). Expression of the 
GRK2 DNM did not prevent PKC-mediated MOPr desensitization on morphine application 
(Bailey et al., 2009a). In contrast, in hippocampal dentate gyrus GRK3 knockout reduced 
morphine-induced desensitization (Terman et al., 2004). 
 
Until very recently there have been no small molecule selective, membrane permeable 
inhibitors of GRKs. In this paper we have examined the effects of a novel small molecule 
inhibitor of GRK2 and GRK3, Takeda Compound 101 (Cmpd101) (Ikeda et al., 2007; Thal et 
al., 2011), as well as GRK3 knockout and signalling kinase inhibitors on the rapid 
desensitization of the MOPr-activated inwardly rectifying potassium current (GIRK) in LC 
neurons. We have sought to address several questions relating to the role of GRKs in MOPr 
desensitization. First, are GRK2 and GRK3 involved in the acute MOPr desensitization 
induced by high intrinsic efficacy agonists, arrestin-biased agonists and lower intrinsic 
efficacy agonists? Second, do both GRK2 and GRK3 play a role in MOPr desensitization? 
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Third, are multiple kinases such as GRKs and ERKs involved in acute MOPr 
desensitization? 
 
Our results suggest that GRK2, and potentially GRK3, but not ERK1/2 or JNK are involved in 
MOPr desensitization by all of the MOPr agonists studied. However, even at concentrations 
of Cmpd101 that almost completely inhibited MOPr phosphorylation at Ser375 and MOPr 
internalization in HEK 293 cells the inhibition of agonist-induced loss of functional MOPr in 
LC neurons was only of the order of 34%. 
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Materials and Methods 
Brain slice preparation 
Male Wistar Rats (5 - 8 weeks old) were killed by cervical dislocation and male mice (wild 
type and GRK3 knockout mice backcrossed onto C57Bl/6 background, 5 - 8 weeks old) were 
decapitated under isoflurane-induced anaesthesia.  Brains were removed and submerged in 
ice-cold cutting solution containing (in mM): 20 NaCl, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 1.25 
NaH2PO4, 85 sucrose, 25 D-glucose and 60 NaHCO3, saturated with 95% O2/5% CO2.  
Horizontal brain slices (230 µm thick) containing the LC were prepared using a vibratome 
(VT1000S, Leica Biosystems, Milton Keynes, UK). Slices were then transferred to artificial 
cerebrospinal fluid (aCSF) composed of (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 
1.2 NaH2PO4, 11.1 D-glucose, 21.4 NaHCO3, and 0.1 ascorbic acid, saturated with 95% 
O2/5% CO2 at 33 oC, and were left to equilibrate for at least 1 h prior to recording.  All 
experiments were performed in accordance with the UK Animals (Scientific Procedures) Act 
1986, the European Communities Council Directive 1986 (86/609/EEC) and the University of 
Bristol and University of Washington ethical review documents as appropriate. 
Whole-cell path-clamp recording 
Slices were submerged in a slice chamber (Warner Instruments, Hamden CT, USA) 
mounted on a microscope stage (BX51WI, Olympus, Southend-on-Sea, UK) and superfused 
(2.5 - 3 ml/min) with aCSF at 33 oC. LC neurons were visualized using Nomarski optics 
using infrared light. Whole-cell patch clamp recordings were made using electrodes (3-6 
MΩ) filled with (in mM): 115 K-methylsulfonate, 10 NaCl, 2 MgCl2, 10 HEPES, 6 EGTA, 2 
MgATP, and 0.5 Na2GTP (pH 7.25, osmolarity 270 mOsm).  Recordings of whole-cell 
currents were filtered at 1 kHz using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale CA, USA) and analysed off-line using WinEDR and WinWCP (University of 
Strathclyde, Glasgow, UK), and pClamp (Molecular Devices, Sunnyvale CA, USA). 
LC neurons were voltage clamped at -60 mV with correction for a -12 mV liquid 
junction potential. Activation of MOPr receptors and α2 adrenoceptors (α2 AR) evoked 
inwardly rectifying potassium channel (GIRK) currents. All drugs were applied in the 
MOL #98293 
 
10 
 
superfusing solution in known concentrations. In those experiments in which α2AR 
responses were studied, noradrenaline (NA) was applied in the presence of prazosin (1 µM) 
and cocaine (3 µM).  Because GIRK currents were much smaller in mouse LC, responses in 
mice were measured in the presence of the glutamate receptor antagonist 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX, 10 µM) and the GABAA receptor antagonist bicuculline 
(10 µM) to inhibit spontaneous excitatory and inhibitory postsynaptic currents. 
Cell culture 
Human embryonic kidney 293 cells (HEK 293) cells stably over expressing haemagglutinin-
tagged rat MOPr (HA-MOPr) were cultured at 37 °C in 5% CO2 in Dulbecco’s modified 
Eagles’s medium (DMEM) supplemented with 10 % fetal bovine serum, 10 U/ml penicillin, 10 
mg/ml streptomycin (Invitrogen, Life Technologies, Paisley UK) and 250 µg/ml G418 (Merck, 
Nottingham, UK). Cells were seeded onto 60 mm dishes and grown to 90 % confluence then 
subjected to serum starvation for 24 h.   
WGA-enrichment of HA-MOPr 
Glycosylated HA-MOPr was enriched from cells that were lysed in pull down buffer (PDB) 
composed of (in mM) 20 HEPES [pH 7.4], 150 NaCl, 1 Na3VO4, 10 β-glycerophosphate, 50 
NaF, 1 PMSF and 5 EDTA plus 1% Triton X-100, 10% glycerol, 0.1% SDS, 2 µg/ml 
leupeptin, 2 µg/ml aprotinin and 1 µg/ml pepstatin A.  The protein concentration of clarified 
cell lysate was adjusted to 1.5 mg/ml and an input sample removed for Western blot 
analysis.  2.25 mg of cell lysate was then incubated with 15 µl sedimented wheat germ 
agglutinin (WGA)-agarose beads (L1394, Sigma Aldrich, Dorset UK), prewashed in PDB and 
incubated overnight at 4 °C.  Beads were then washed three times in PDB for 5 min at 4 °C.  
WGA-binding proteins were eluted with the addition of SDS-sample buffer and boiling at 95 
°C for 4 min.   
Western blotting 
Eluted WGA-binding proteins and input sample were supplemented with β-mercaptoethanol 
for gel loading.  Samples were subject to SDS polyacrylamide gel electrophoresis and 
proteins transferred onto polyvinylidene fluoride (PVDF) membranes.  For detection of 
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agonist-induced receptor phosphorylation antibodies targeting pSer375 on MOPr were used 
(dilution 1:1000, Cell Signalling Technology, Danvers, MA) and total receptor levels detected 
with anti-HA antibody (MMS-101R-200, 1:1000, Cambridge Bioscience Limited, Cambridge 
UK).  For input samples, anti-pERK1/2, anti-ERK1/2 and anti-pElk-1 (#9101, #9107, #9181 
each 1:1000, Cell Signalling Technology) and anti-tubulin antibodies were used (T6074, 
1:10000, Sigma Aldrich).  Following incubation with the species appropriate horseradish 
peroxidise (HRP)-conjugated secondary antibody (NA934V, donkey anti-rabbit, dilution 
1:7500; NA931V, sheep anti-mouse, 1:10000, GE Healthcare, Buckinghamshire UK), bands 
were visualized by enhanced chemiluminescence (ECL) with SuperSignal West Dura 
Chemiluminescent Substrate (Thermo Fisher Scientific, Hemel Hempstead, UK). 
Densitometry of bands was undertaken using ImageJ (NIH, USA), duplicate values were 
taken for each sample and then averaged. pSer375 levels were normalized against 
corresponding total HA-MOPr levels and pERK1/2 against total ERK1/2 levels determined in 
the same experiment. 
Internalization Assays 
DAMGO-induced internalization of HA-MOPr was assessed by ELISA as previously 
described (Johnson et al., 2006) and by confocal microscopy imaging (Mundell et al., 2006). 
HEK 293 cells stably expressing HA-MOPr were prelabelled with primary antibody for 1 h at 
4 °C before incubation with Cmpd101 (3 or 30 µM) for 30 min at 37 °C. Cells were then 
stimulated with DAMGO (10 µM) at 37 °C to induce internalization. In the ELISA changes in 
surface receptor expression were subsequently determined by normalizing data from each 
treatment group to corresponding control surface receptor levels determined from cells not 
exposed to DAMGO in the same experiment. For confocal imaging cells were imaged using 
a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM16000 
inverted epifluorescence microscope with a pLApoBL 63 x oil immersion objective. 
Arrestin Translocation Assay 
For the arrestin-3 recruitment assay, PathHunterTM cells and accompanying assay kit were 
obtained from DiscoveRx (Birmingham, UK). These cells are U2OS (human osteosarcoma) 
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cells stably expressing tagged human MOPr and tagged arrestin-3 such that recruitment of 
arrestin-3 to the receptor leads to reconstitution of β-galactosidase activity which is 
measured by luminescence in a plate reader (McPherson et al., 2010). The experiments 
were undertaken exactly as described in the manufacturer’s instructions, with the agonist 
DAMGO being added to the cells for 90 min, and where applicable Cmpd101 being added 
alone or 30 min before DAMGO. 
Kinase Screen 
The express kinase screen was performed at the Medical Research Council International 
Centre for Kinase Profiling (Dundee, UK). The screen was comprised of 52 human enzymes 
providing a representative sampling of the kinome, with the exception of lipid kinases. The 
method used was a radioactive filter binding assay using 32ATP which provides a direct 
measure of kinase activity (Hastie et al., 2006; Bain et al., 2007). Cmpd101 was studied at a 
concentration of 1 µM. Results are given as the percentage of kinase activity in the absence 
of the inhibitor.  The ATP concentrations used were at or below the calculated Km for ATP for 
each individual kinase.  The screen was performed in duplicate and results are given as a 
mean value with standard deviation.   
Quantification of DAMGO-induced  loss of functional MOPr 
Following desensitization of MOPr by bath-application of DAMGO, DAMGO was replaced by 
morphine. Using the operational model of agonism (Black et al., 1985), transducer ratio (tau) 
values for morphine were calculated (as in Bailey et al., 2009b). Percentage loss of receptor 
responsiveness (f) was then calculated using the equation f = 100 x (1 - tau2/tau1) where 
tau1 is the value in control slices and tau2 is the value after DAMGO-induced desensitization 
(Lohse et al., 1990). 
Statistics 
Data are presented as means  ±  standard errors and were analysed by unpaired two-tailed 
Student’s t-tests, one-way or two-way ANOVA with Bonferroni post-hoc test as appropriate 
using Prism5 (Graphpad Software Inc., San Diego CA, USA). Differences were assumed to 
be significant at P<0.05. 
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Drugs and compounds 
3-[[[4-Methyl-5-(4-pyridyl)-4H-1,2,4-triazole-3-yl] methyl] amino]-N-[2-(trifuoromethyl) benzyl] 
benzamidehydrochloride (Cmpd101 hydrochloride) was synthesized at the University of Bath 
(Bath, UK) in 9 steps from isonicotinic acid hydrazide (Ikeda et al., 2007). Analysis of the 
final compound (as the free base) provided data consistent with the structure with purity 
>99% (by 13C nmr): 1H NMR (400 MHz, CDCl3) δ8.71 (dd, J = 1.6 Hz, J = 4.4 Hz, 2H); 7.63-
7.45 (m, 5H); 7.34 (t, J = 7.6 Hz, 1H); 7.25-7.24 (m, 1H); 7.18 (t,J = 7.6 Hz, 1H); 7.06 (d,J = 
6.8 Hz, 1H); 6.91-6.85 (m, 2H); 4.76 (d, J = 6.00 Hz, 2H), 4.50 (s, 2H); 3.71 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 167.6, 153.8, 153.2, 150.3, 147.5, 136.6, 135.2, 134.4, 132.3, 130.2, 
129.5, 128.1, 127.8, 127.5, 126.0, 125.9, 125.8, 125.7, 123.1, 122.5, 116.6, 116.3, 111.9, 
76.7, 40.5, 39.3, 31.6, ESIMS: calc. for C24H21F3N6NaO, 489.1627; found 489.1701. 
D-Ala2,N-MePhe4,Gly-ol]-enkephalin (DAMGO) and methionine enkephalin (Met Enk), 
(Bachem, Bubendorf, Switzerland); morphine hydrochloride (Macfarlane-Smith, Edinburgh 
UK); cocaine hydrochloride (Sigma Aldrich); endomorphin-2, bicuculline, 6-cyano-7-
nitroquinoxaline-2,3-dione disodium (CNQX), naloxone hydrochloride, noradrenaline 
bitartrate, prazosin hydrochloride, Y-27632, amlexanox (Ascent Scientific / Abcam 
Biochemicals, Cambridge, UK); GF109203X, GSK 650384, PD 98059 (Tocris Bioscience, 
Bristol, UK). All other reagents were from Sigma Aldrich. 
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RESULTS 
Role of GRK2 and GRK3 in acute MOPr desensitization induced by Met Enk or 
DAMGO. 
In rat LC neurons, activation of MOPrs by receptor-saturating concentrations of Met Enk (30 
µM), DAMGO (10 µM) or endomorphin-2 (10 µM) elicited outward current through GIRK 
channels that rapidly desensitized in the presence of the drug, with only about 50% of the 
initial current remaining after 10 min exposure (Fig. 1). To examine the role of GRK2 and 
GRK3 in the Met Enk-induced desensitization, LC slices were pre-treated with the inhibitor, 
Cmpd101, at concentrations previously shown to inhibit desensitization of β2 adrenoceptors 
in HEK 293 cells (Ikeda et al., 2007). Cmpd101 concentration-dependently reduced the 
amount of Met Enk-induced desensitization (Fig. 1A-C) such that in the presence of 
Cmpd101 (30 µM) the desensitization induced by Met Enk (30 µM) was reduced to only 
15%. We also observed that Cmpd101 reduced the amount of desensitization induced by 
DAMGO (10 µM, Fig. 1D-F) and endomorphin-2 (10 µM, Fig. 1G-I).  
 
To determine whether there was any additional role for ERK1/2, PKC or JNK in MOPr 
desensitization we exposed cells to Cmpd101 and PD98059 (10 µM) to inhibit ERK1/2 (Met 
Enk as agonist, Fig. 1C), SP600125 (30 µM) to inhibit JNK (Met Enk as agonist, Fig. 1C), or 
GF109203X (1 µM) to inhibit PKC (DAMGO as agonist, Fig. 1F). We did not observe any 
further reduction in desensitization in the presence of the ERK1/2, PKC, or JNK inhibitors. 
Neither the ERK1/2 nor JNK inhibitor applied on its own in the absence of Cmpd 101 
affected Met Enk-induced desensitization (Control: 51 ±  6%, n=5; + 10 µM PD98059: 43 ± 
5%, n=5; + 30 µM SP600125: 50 ± 4%, n=5). Amlexanox has recently been identified as a 
GRK5 inhibitor (Homan et al., 2014b). When cells were exposed to Cmpd101 and 
amlexanox (50 µM) there was no further reduction in desensitization compared with 
Cmpd101 alone (Fig. 1C). Amlexanox applied on its own in the absence of Cmpd101 did not 
affect Met Enk-induced desensitization (% Met Enk-induced desensitization in 50 µM 
amlexanox alone: 51 ± 3%, n=5). 
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The inhibition of MOPr desensitization that we observed with Cmpd101 does not appear to 
be due to it acting as a MOPr antagonist to reduce the number of receptors being activated. 
When a submaximal concentration of Met Enk (600nM) was applied before and following 
exposure of cells to Cmpd101 (3 µM for 15 min), the Met Enk response in the presence of 
Cmpd101 was not different from the initial response before Cmpd101 (94 ± 13% of initial 
response, n=4, one-sample t-test vs. 100%, p>0.05).  
 
Role of GRK2 and GRK3 in morphine-induced MOPr desensitization 
Although morphine produces much less acute MOPr desensitization in LC neurons 
compared to either Met Enk or DAMGO (Bailey et al., 2004; 2009a), the morphine response 
did desensitize by about 25% over a 15 min application (Fig. 1J-L).  Pre-treatment with 
Cmpd101 (30 µM) significantly reduced the morphine-induced desensitization.  This 
suggests that GRK2 and GRK3 are not only involved in desensitization to higher efficacy 
MOPr agonists such as Met Enk and DAMGO, but are also involved in desensitization to the 
partial agonist morphine in the absence of PKC activation. 
 
MOPr desensitization in LC neurons from GRK3 knockout mice 
Cmpd101 was previously shown to be almost equally effective at inhibiting GRK2 and GRK3 
(Thal et al., 2011). GRK3 KO has been reported to abolish the desensitization induced by 
fentanyl and morphine in rat hippocampal dentate gyrus neurons (Terman et al., 2004). To 
determine whether GRK3 was the sole isoform required for MOPr desensitization in LC 
neurons, we measured Met Enk-induced desensitization in LC neurons prepared from GRK3 
KO mice. The amplitude of the Met Enk-induced current was similar in neurons from both 
GRK3 KO and wild type (WT) mice (WT: 72 ± 10 pA, n=6; GRK KO: 58 ± 11 pA, n=6, 
p>0.05). Met Enk-induced desensitization measured after 10 min of Met Enk application was 
also not significantly different in GRK3 KO neurons compared to WT controls (Fig. 2A-B). To 
ensure that there was not a species-specific difference in the mechanism of desensitization, 
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we also examined the ability of Cmpd101 to inhibit Met Enk-induced desensitization in 
mouse LC neurons since the previous experiments with Cmpd101 were performed in rat LC 
neurons.  In LC neurons from C57Bl/6J WT mice, Met Enk produced a similar amount of 
desensitization (45%) to that observed in rat neurons after a 10 min application.  Cmpd101 
inhibited the Met Enk-induced desensitization in WT mouse LC neurons, being maximally 
effective at the lower (3 µM) concentration (Fig. 2C-D).   
 
These results suggest first that GRK2 plays a role in Met Enk-induced desensitization in LC 
neurons and second, either that GRK3 plays no role in Met Enk-induced desensitization in 
LC neurons or that GRK3 is not solely responsible. However, as Cmpd101 is a mixed 
GRK2/3 inhibitor, we cannot exclude the possibility that both GRK2 and GRK3 are involved 
and that removal of only one (in our current experiments GRK3) is insufficient to inhibit 
desensitization. 
 
Loss of functional MOPrs underlying acute MOPr desensitization 
There is a significant MOPr reserve in LC neurons, that needs to be removed (i.e. 
desensitized) before any decrease in the response to a supramaximal concentration of a full 
agonist such as Met Enk or DAMGO can be detected and therefore the true proportion of 
receptors that have been desensitized is hard to assess from responses such as those 
shown in Fig. 1 (Connor et al., 2004). To determine the actual loss of functional MOPrs 
following desensitization we used a previously developed protocol that measures the 
decrease induced by desensitization of the maximum response to the partial agonist 
morphine (Bailey et al., 2009b). For a partial agonist, the maximum response occurs when 
all the receptors are occupied and therefore any decrease in maximum response is directly 
related to a loss of receptor function. To be able to compare results from different neurons, 
the morphine response in each was normalized to the response to noradrenaline (NA, 100 
µM), which activates α2ARs that couple to the same pool of GIRKs in LC neurons (North and 
Williams, 1985). 
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In control LC neurons the maximum response evoked by morphine was 85% of the 
maximum response to NA (100 µM) (Fig. 3A). To examine the reduction in morphine 
response caused by DAMGO-induced MOPr desensitization, neurons were first treated with 
DAMGO (10 µM) for 12 min to induce desensitization, then the maximum response to 
morphine (30 µM) was determined at plateau (6 mins after DAMGO was replaced by 
morphine; Fig. 3B & C). In neurons that were first treated with DAMGO (10 µM) for 12 min to 
induce desensitization the maximum response to morphine was reduced by over 80% (Fig. 
3B). Using the operational model of agonism (Black et al., 1985) to estimate the actual loss 
of functional MOPrs induced by DAMGO (for details see Bailey et al., 2009b and Methods 
section) we calculate that the DAMGO treatment induced a 93% loss of functional MOPrs. 
When we repeated the experiment but this time in the presence of Cmpd101 (3 or 30 µM) 
the desensitization induced by DAMGO was markedly reduced as was the reduction in the 
maximum response to morphine (Fig. 3C & D). In the presence of 30 µM Cmpd101 the 
desensitization induced by DAMGO (10 µM) reduced the maximum response to morphine by 
only 44% which equates to a 59% loss of functional MOPrs. Thus whilst Cmpd101 reduced 
the DAMGO-induced loss of functional receptors from 93 to 59% this reduction was sufficient 
to produce a marked reduction in the desensitization observed during application of a 
receptor-saturating concentration of agonist (Fig. 1). 
 
Overall our findings with Cmpd101 suggest that GRK2 and possibly also GRK3 are involved 
in both Met Enk- and DAMGO-induced desensitization of MOPr, but it is clear that there is a 
component of desensitization that still remains in the presence of the drug either because of 
incomplete inhibition of GRK2 and GRK3 by Cmpd101 or because an additional Cmpd101-
resistant mechanism of desensitization exists. 
 
MOPr phosphorylation, internalization and arrestin translocation 
MOL #98293 
 
18 
 
To assess the ability of Cmpd101 to inhibit GRK in intact cells we next examined agonist-
induced MOPr phosphorylation, arrestin translocation and MOPr internalization. Because 
these processes are more difficult to assess in neurons in a brain slice, we instead examined 
them in cell lines stably expressing MOPrs.  Phosphorylation of HA-tagged MOPr was 
measured by Western blotting using the commercially available antibody that recognizes the 
phosphorylated residue Ser375 in the MOPrC-terminal tail. We have previously demonstrated 
that in vitro GRK2 directly phosphorylates Ser375 (Chen et al., 2012).  Application of DAMGO 
(10 µM) for 5 min produced a robust phosphorylation of Ser375 that was partially inhibited by 
pre-treatment of cells for 30 min with 3 µM Cmpd101 and fully blocked by pre-treatment with 
30 µM Cmpd101 (Fig. 4A & B). Cmpd101 (30 µM) also prevented phosphorylation of MOPr 
at Thr370, Thr376 and Thr379 residues also known to be phosphorylated by GRKs (Sanderson & 
Kelly, unpublished observations).  
 
Translocation of arrestin3 to agonist-activated MOPr was assessed using the DiscoveRx 
PathHunterR assay. Application of DAMGO (10 µM for 90min) led to a large recruitment of 
arrestin3 to MOPr which was dramatically reduced by in the presence of Cmpd101 (30 µM) 
(Fig. 4C). 
 
We assessed internalization of HA-tagged MOPrs by ELISA and confocal microscopy using 
an anti-HA antibody to label surface receptors.  DAMGO (10 µM) application induced MOPr 
internalization in a time-dependent manner and Cmpd101 markedly reduced DAMGO-
induced MOPr internalization (Fig. 4D& E).  
 
These data demonstrate that Cmpd101 was able to block DAMGO-induced MOPr 
phosphorylation on Ser375, arrestin recruitment, and MOPr internalization presumably by 
inhibiting GRK2 and GRK3. This contrasts somewhat with our data from LC neurons where 
although Cmpd101 could reduce agonist-induced desensitization the extent of the reduction 
was only about 34% when calculated as loss of functional receptors. 
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ERK1/2 phosphorylation 
It has previously been reported that GRK2 and GRK3 inhibition alone was not sufficient to 
inhibit Met Enk-induced desensitization in mouse LC neurons but that a combination of 
GRK2, GRK3 and ERK1/2 inhibition was required i.e. there was overlap and redundancy 
between GRK and ERK1/2 in MOPr desensitization (Dang et al., 2009).  To confirm that 
Cmpd101 did not inhibit ERK1/2 activity, we measured both the phosphorylation of ERK1/2, 
which is often used as a measure of its activity (Roskoski, 2012) and the phosphorylation of 
Elk-1 by ERK1/2 (Cruzalegui et al., 1999) in HEK 293 cells stably expressing HA-tagged 
MOPrs.  Cmpd101 did not affect the DAMGO-induced (10 µM, 5 min) increase in ERK1/2 
phosphorylation (Fig. 5A & B).  Moreover, at 30 µM Cmpd101 on its own produced a small 
increase in basal ERK1/2 phosphorylation (Fig. 5A & B).  Similarly, Cmpd101 (30 µM) did 
not inhibit the DAMGO-induced (10 µM, 5 min) increase in Elk-1 phosphorylation (Fig. 5C & 
D). The ERK1/2 activation inhibitor, PD98059, significantly decreased both DAMGO-induced 
ERK1/2 and Elk-1 phosphorylation (Fig. 5E). 
 
Thus, the ability of Cmpd101 to decrease MOPr desensitization in the LC is unlikely to be 
due to an inhibition of ERK1/2 activity in combination with the inhibition of GRK activity. 
 
Selectivity of kinase inhibition by Cmpd101 
Cmpd101 has previously been shown to be highly selective for GRK2 and GRK3 over other 
GRK isoforms (Ikeda et al., 2007; Thal et al., 2011). We subjected Cmpd101 to a further 
kinase screen at the Medical Research Council International Centre for Kinase Profiling 
(Dundee, UK) to determine whether it inhibited the activity of other non-GRK kinases. As this 
screen was conducted on purified kinases in vitro we performed the screen using 1 µM 
Cmpd101 (i.e. 30x the reported IC50 for inhibition of GRK2 in in vitro purified enzyme assay 
conditions). Of the kinases that have previously been implicated in MOPr desensitization, 
Cmpd101 inhibited the activity of PKC, PKA, JNK, CaMKII and ERK1/2 in vitro by less than 
MOL #98293 
 
20 
 
20% at 1 µM (Supplementary Data Table 1 and Supplementary Figure 1).  Cmpd101 
inhibited only 5 off-target kinases by more than 50%; these included protein kinase C related 
protein kinase (PRK2) and serum and glucocorticoid regulated kinase (SGK1) which were 
inhibited by 93% and 69% respectively.  To test whether either of these kinases might be 
involved in DAMGO-induced desensitization, we pre-treated rat LC slices with established 
inhibitors of these kinases.  GSK650394 (10 µM) is an inhibitor of SGK1 and Y-27632 (50 
µM) is an inhibitor of both PRK2 and ROCK2 which Cmpd101 also inhibited by 47% in the 
kinase screen.  LC neurons pre-treated with a combination of these two kinase inhibitors did 
not show any difference in the amount of desensitization induced by a 10 min application of 
DAMGO (30 µM) compared to that observed in control neurons (Supplementary Figure 2).  
Therefore, these off target actions of Cmpd101 do not appear to play a role in the inhibition 
of MOPr desensitization by Cmpd101. 
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Discussion  
We have studied the effects of Cmpd101, a novel membrane permeable, small molecule 
inhibitor of both GRK2 and GRK3 on agonist-induced MOPr desensitization in LC neurons. 
Cmpd101 has previously been reported to be a potent inhibitor of GRK2 and GRK3, with 
reported IC50 values of 35 nM (Ikeda et al., 2007) or 290 nM (Thal et al., 2011) under 
different in vitro purified enzyme assay conditions, but has no activity against GRK5 at 
concentrations up to 125 µM (Thal et al., 2011). In intact cell assay conditions, higher 
concentrations are required, with Cmpd101 showing concentration-dependent inhibition of β2 
adrenoceptor desensitization in HEK 293 cells over the range 3 – 30 µM (Ikeda et al., 2007). 
 
In our preliminary kinase screen Cmpd101 showed high selectivity when tested across a 
broad range of kinases with only the AGC kinases, PRK2, MSK1 and SGK1, being inhibited 
by over 50% in the presence of 1 µM Cmpd101. These kinases all sit in regions of the 
kinome (Manning et al., 2002) close to GRK2 and GRK3 (see Supplementary data Fig. 1), 
although PRK2 and SGK1 appear to play no role in MOPr desensitization (see 
Supplementary data Fig. 2). Other approaches previously taken to inhibit GRKs include the 
broad spectrum kinase inhibitor, staurosporine (Arttamangkul et al., 2012), the PKC/GRK 
inhibitor Ro32-0432 (Hull et al., 2010), ‘β-ARK-1 inhibitor’ (Iino et al., 2002; Hull et al., 2010) 
and the antidepressant drug paroxetine (Thal et al., 2012; Homan et al., 2014a). However, 
none of these approaches combine the cell-permeable, potency and selectivity profiles of 
Cmpd101. Moreover, Cmpd101 shows specificity between GRK2/3 and GRK5. Across a 
range of opioid agonists with different intrinsic efficacies for G protein activation (Met Enk, 
DAMGO and morphine) and arrestin bias (endomorphin 2) we observed that Cmpd101 
reduced the desensitization of the opioid-activated GIRK current indicating the involvement 
of GRK2 and/or GRK3 in this desensitization. The effective concentrations of Cmpd101 in 
these whole cell assays was 100 – 1000 fold higher than the concentrations that inhibit 
GRK2 and GRK3 in vitro. This likely results from low permeability of the molecule across the 
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cell membrane but could also be due to other factors such as differences in the conformation 
or properties of the kinases in a cellular environment.  
 
Our observation that MOPr desensitization in LC neurons was unaffected by GRK3 knockout 
indicates that in these neurons GRK3 is not solely responsible for MOPr desensitization. 
This observation is different from what has been reported previously in the hippocampal 
dentate gyrus where fentanyl-induced MOPr desensitization was absent in brain slices 
prepared from GRK3 KO mice (Terman et al., 2004). Suggesting that different mechanisms 
of MOPr desensitization may be present in different brain regions. This difference could 
result from differential expression of GRK isoforms in different neuronal populations. In situ 
hybridisation studies in rats have shown ubiquitous expression of GRK2, 3 and 6 throughout 
the brain (Erdtmann-Vourliotis et al, 2001), with expression of GRK2, 3, 5 and 6 in the LC 
but no studies have performed quantitative analysis of GRK isoform protein levels in different 
brain regions. Although GRK2 KO is embryonic lethal, selective inhibition of GRK2 in the 
GRK2as5 transgenic mouse has also been reported not to affect Met Enk-induced 
desensitization in LC neurons (Quillinan et al., 2011). Further, although overexpression of a 
GRK2 dominant negative mutant (DNM) reduced DAMGO-induced MOPr desensitization in 
rat LC neurons (Bailey et al., 2009a), this DNM construct is likely to also inhibit GRK3, based 
on homology of the GRK2 and GRK3 isoforms. Given that Cmpd101 is a potent inhibitor of 
both GRK2 and GRK3 our data suggest that in LC neurons there is an overlap and 
redundancy of GRK2 and GRK3 such that KO of only one (e.g. GRK3) is insufficient to 
inhibit desensitization.  
 
Cmpd101 inhibited agonist-induced phosphorylation of MOPr at Ser375 and the subsequent 
internalization of the receptor in HEK 293 cells. Several groups have previously 
demonstrated that GRK2 and GRK3 rapidly phosphorylate MOPr. Purified GRK2 
phosphorylates Ser375 in the C-terminal tail in vitro (Chen et al., 2012). Using phosphosite-
specific antibodies DAMGO and other higher efficacy agonists have been observed to 
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phosphorylate several amino acid residues in the C-terminal tail of MOPr (Doll et al., 2011, 
2012; Just et al., 2013). Phosphorylation at Ser375 appears to be the initiating event but 
thereafter flanking residues (Thr370, Thr376, and Thr379) are subsequently phosphorylated in a 
hierarchical manner. This higher-order phosphorylation has been shown to be mediated by 
GRK2 and GRK3 in that it is reduced by siRNA knockdown of these GRK isoforms. 
Furthermore, mutation of Ser375, Thr376 and Thr379 to Ala prevented DAMGO-induced MOPr 
internalization in medium spiny striatal neurons (Just et al., 2013). Morphine, a MOPr partial 
agonist in the LC, has previously been shown to produce much less acute MOPr 
desensitization in LC neurons (Alvarez et al., 2002; Bailey et al., 2003) than high efficacy 
MOPr agonists. It has also been shown to induce less phosphorylation of Ser375, no 
phosphorylation of Thr376 or Thr379 (Just et al., 2013) and less arrestin translocation 
(McPherson et al., 2010). In the present study we observed that Cmpd101 partially inhibited 
morphine-induced MOPr desensitization in LC neurons.  
 
Our studies with Cmpd101 support the view that GRK2 and GRK3 do play a role in MOPr 
desensitization in LC neurons. What was surprising is that when we calculated the loss of 
MOPr function resulting from agonist-induced desensitization we found that Cmpd101 only 
partially reversed the loss of MOPr function that underlies the desensitization. The inability of 
Cmpd101 to fully reverse the loss of MOPr function induced by DAMGO could indicate either 
that there are two mechanisms of MOPr desensitization – one involving GRK mediated 
phosphorylation (inhibited by Cmpd101) and one that does not involve GRK2 and GRK3 – or 
that, in intact neurons, for reasons that are unclear, Cmpd101 does not completely inhibit 
GRK2 and GRK3. Evidence against the incomplete GRK inhibition hypothesis would be that 
in HEK 293 cells Cmpd101 very effectively reduced DAMGO-induced MOPr 
phosphorylation, arrestin translocation and MOPr internalization. However, one caveat to 
this is that, by necessity the phosphorylation, translocation and internalization studies were 
performed under very different experimental conditions to the electrophysiological 
experiments. If there is a second mechanism involved in MOPr desensitization this is 
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currently unidentified, but it does not involve ERK1/2, PKC or JNK as in the present study 
inhibitors of these kinases did not reduce MOPr desensitization further in the presence of 
Cmpd101. One potential alternative mechanism for the residual component of MOPr 
desensitization is that catalytically-inactive GRK2/3 binds βγ subunits of the G-protein, 
inhibiting GIRK channel function (Raveh et al., 2010), while we cannot rule this out previous 
work suggests that this process does not play a role in rat LC neurons of this age (Llorente 
et al., 2012). Of the other GRK subtypes expressed in mammalian neurons (GRK5 and 
GRK6), our data suggest that GRK5 is not responsible, as the GRK5 inhibitor, amlexanox, 
was ineffective. Although amlexanox lacks specificity (Reilly et al., 2013), and we have no 
direct proof that it is permeating LC neurons in the slice, it has been shown to inhibit 
intracellular GRK5-mediated responses, with near complete block at 50 µM (Homan et al., 
2014b). It is not currently known if amlexanox also inhibits the structurally-similar GRK6, 
although previous studies (Bailey et al., 2009b) have shown no effect of GRK6 on MOPr 
desensitization using viral-transfection of dominant negative mutant GRK6. 
 
We have been unable to obtain any evidence to support the view that ERK1/2 participate in 
MOPr desensitization as proposed by Dang et al., (2009).  In our preliminary in vitro kinase 
screen Cmpd101 did show some inhibition of both ERK1 and ERK2 but this was modest 
(20% inhibition) with a concentration of Cmpd101 that would inhibit GRK2 by over 90%. 
However we found no evidence in intact cells that Cmpd101 could decrease ERK1/2 
phosphorylation or inhibit the phosphorylation of Elk-1 by ERK1/2. Thus we have excluded 
the possibility that Cmpd101 inhibits MOPr desensitization by inhibiting both GRK2/3 and 
ERK1/2.  
 
In conclusion, we demonstrate that Cmpd101 offers a simple means to study the roles of 
GRK2/3 in GPCR desensitization and other cellular functions. We show here that a 
component of MOPr desensitization in rodent LC neurons is GRK2/3-mediated. Data from 
GRK3 knockout mice demonstrate that GRK3 ablation alone is insufficient to inhibit MOPr 
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desensitization in these neurons, suggesting either a selective role for GRK2, or, 
redundancy of action between GRK2 and GRK3. The development of a membrane-
permeable, small-molecule inhibitor of GRK2/3 gives the opportunity to explore the roles of 
these kinases in desensitization of MOPRs, and other GPCRs, in native tissues and in vivo.  
 
 
  
MOL #98293 
 
26 
 
Acknowledgements 
The authors thank John Tesmer (University of Michigan) for help and guidance with the 
synthesis of Compound101. 
 
  
MOL #98293 
 
27 
 
Authorship contributions 
Participated in research design: Bailey CP, Kelly E, Lowe JD and Henderson G. 
 
Conducted experiments: Cooke AE, Kelly E, Lowe JD, Sanderson HS, Withey SL and 
Tsisanova E 
 
Contributed new reagents or analytic tools: Chavkin C, Husbands SM and Ostovar M 
 
Performed data analysis: Cooke AE, Kelly E, Lowe JD, Sanderson HS and Tsisanova E. 
 
Wrote or contributed to the writing of the manuscript: Lowe JD, Kelly E, Henderson G and 
Bailey CP.  
MOL #98293 
 
28 
 
References 
Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M, Grandy DK, 
Williams JT (2002) mu-Opioid receptors: Ligand-dependent activation of potassium 
conductance, desensitization, and internalization. J Neurosci 22:5769-5776. 
Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT (2008) 
Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 
74:972-979. 
Arttamangkul S, Lau EK, Lu HW, Williams JT (2012) Desensitization and trafficking of μ-
opioid receptors in locus ceruleus neurons: modulation by kinases. Mol Pharmacol 81:348-
355. 
Arttamangkul S, Birdsong W, Williams JT (2015) Does PKC activation increase the 
homologous desensitization of μ opioid receptors? Br J Pharmacol 172:583-592. 
Bailey CP, Couch D, Johnson E, Griffiths K, Kelly E, Henderson G. (2003) Mu-opioid 
receptor desensitization in mature rat neurons: lack of interaction between DAMGO and 
morphine. J Neurosci 23:10515-10520. 
Bailey CP, Kelly E, Henderson G (2004) Protein kinase C activation enhances morphine-
induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons. 
Mol Pharmacol 66:1592-1598. 
Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, McArdle CA, 
Smith FL, Dewey WL, Kelly E, Henderson G (2009a) Involvement of PKC alpha and G 
protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors 
in mature brain neurons. Br J Pharmacol 158:157-164. 
MOL #98293 
 
29 
 
Bailey CP, Llorente J, Gabra BH, Smith FL, Dewey WL, Kelly E, Henderson G (2009b) Role 
of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine 
in rat locus coeruleus neurons. Eur J Neurosci 29:307-318. 
Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi 
DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 
408:297-315. 
Black JW, Leff P, Shankley NP, Wood J (1985) An operational model of pharmacological 
agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J 
Pharmacol 84:561-571. 
Chen YJ, Oldfield S, Butcher AJ, Tobin AB, Saxena K, Gurevich VV, Benovic JL, Henderson 
G, Kelly E (2013) Identification of phosphorylation sites in the COOH-terminal tail of the μ-
opioid receptor. J Neurochem 124:189-199. 
Connor M, Osborne PB, Christie MJ (2004) Mu-opioid receptor desensitization: is morphine 
different? Br J Pharmacol 143:685-696. 
Cruzalegui FH, Cano E, Treisman R (1999) ERK activation induces phosphorylation of Elk-1 
at multiple S/T-P motifs to high stoichiometry. Oncogene 18:7948-7957. 
Dang VC, Napier IA, Christie MJ (2009) Two distinct mechanisms mediate acute mu-opioid 
receptor desensitization in native neurons. J Neurosci 29:3322-3327. 
Doll C, Konietzko J, Pöll F, Koch T, Höllt V, Schulz S (2011) Agonist-selective patterns of µ-
opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 
164:298-307. 
Doll C, Pöll F, Peuker K, Loktev A, Glück L, Schulz S (2012) Deciphering µ-opioid receptor 
phosphorylation and dephosphorylation in HEK 293 cells. Br J Pharmacol 167:1259-1270. 
MOL #98293 
 
30 
 
Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, Höllt V (2001) Distribution of G 
protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain 
Res Mol Brain Res 95:129-137. 
Groer CE, Schmid CL, Jaeger AM, Bohn LM (2011) Agonist-directed interactions with 
specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and 
dephosphorylation. J Biol Chem 286:31731-31741. 
Hastie CJ, McLauchlan HJ, Cohen P (2006) Assay of protein kinases using radiolabeled 
ATP: a protocol. Nat Protoc 1:968-971. 
Homan KT, Wu E, Wilson MW, Singh P, Larsen SD, Tesmer JJ (2014a) Structural and 
functional analysis of G protein-coupled receptor kinase inhibition by paroxetine and a 
rationally designed analog.  Mol Pharmacol 85:237-248. 
Homan KT, Wu E, Cannavo A, Koch WJ, Tesmer JJ (2014b) Identification and 
characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules 
19:16937-16949. 
Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, Henderson G, Dewey WL (2010) 
The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance 
induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332:1127-1135. 
Iino M, Furugori T, Mori T, Moriyama S, Fukuzawa A, Shibano T (2002) 
Rational design and evaluation of new lead compound structures for selective betaARK1 
inhibitors. J Med Chem 45:2150-2159. 
Ikeda S, Keneko M, Fujiwara S (2007), inventors; Takeda Pharmaceutical Company Ltd., 
Ikeda S, Keneko M, Fujiwara S, assignees. Cardiotonic agent comprising GRK inhibitor. 
World patent WO2007034846. 2007 March 29. 
MOL #98293 
 
31 
 
Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, 
Bailey CP, Kelly E, Henderson G (2006) Agonist-selective mechanisms of mu-opioid 
receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70:676-685. 
Kelly E, Bailey CP, Henderson G (2008) Agonist-selective mechanisms of GPCR 
desensitization. Br J Pharmacol 153 Suppl 1:S379-388. 
Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, Mann A, Doll C, Trinidad 
JC, Burlingame AL, von Zastrow M, Schulz S (2013) Differentiation of opioid drug effects by 
hierarchical multi-site phosphorylation. Mol Pharmacol 83:633-639. 
Li AH, Wang HL (2001) G protein-coupled receptor kinase 2 mediates mu-opioid receptor 
desensitization in GABAergic neurons of the nucleus raphe magnus. J Neurochem 77:435-
444. 
Llorente J, Lowe JD, Sanderson HS, Tsisanova E, Kelly E, Henderson G, Bailey CP (2012) 
μ-Opioid receptor desensitization: homologous or heterologous? Eur J Neurosci 36:3636-
3642. 
Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ (1990) Multiple pathways of rapid beta 2-
adrenergic receptor desensitisation. Delineation with specific inhibitors. J Biol Chem 
265:3202-3211. 
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase 
complement of the human genome. Science 298:1912-1934. 
McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, 
Rosethorne EM, Charlton SJ, Henderson G, Kelly E (2010) μ-opioid receptors: correlation of 
agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-
766. 
MOL #98293 
 
32 
 
Mittal N, Tan M, Egbuta O, Desai N, Crawford C, Xie CW, Evans C, Walwyn W (2012) 
Evidence that behavioral phenotypes of morphine in β-arr2-/- mice are due to the unmasking 
of JNK signaling. Neuropsychopharmacology 37:1953-1962. 
Mundell SJ, Luo J, Benovic JL, Conley PB, Poole AW (2006) Distinct clathrin-coated pits sort 
different G protein-coupled receptor cargo. Traffic 7:1420-1431. 
North RA, Williams JT (1985) On the potassium conductance increased by opioids in rat 
locus coeruleus neurones. J Physiol 364:265-280. 
Quillinan N, Lau EK, Virk M, von Zastrow M, Williams JT (2011) Recovery from mu-opioid 
receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 
31:4434-4443. 
Raveh A, Cooper A, Guy-David L, Reuveny E (2010) Nonenzymatic rapid control of 
GIRK channel function by a G protein-coupled receptor kinase. Cell, 143:750–760. 
Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White 
NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, Olefsky JM, Saltiel AR 
(2013) An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related 
metabolic dysfunctions in mice. Nat Med 19:313-321. 
Roskoski R (2012) ERK1/2 MAP kinases: Structure, function, and regulation. Pharm Res 66: 
105-143.  
Shenoy SK, Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal 
transduction. Trends Pharmacol Sci 32:521-533. 
Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, Chavkin C (2004) G 
protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid 
withdrawal. Br J Pharmacol 141:55-64. 
MOL #98293 
 
33 
 
Thal DM, Yeow RY, Schoenau C, Huber J, Tesmer JJ (2011) Molecular mechanism of 
selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol 80:294-303. 
Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, 
Cheung JY, Sklar LA, Koch WJ, Tesmer JJ (2012) Paroxetine is a direct inhibitor of g 
protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 
7:1830-1839 
Walwyn W, Evans CJ, Hales TG (2007) Beta-arrestin2 and c-Src regulate the constitutive 
activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci 
27:5092-5104. 
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans 
CJ, Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, 
internalization, and tolerance. Pharmacol Rev 65:223-54.  
MOL #98293 
 
34 
 
Footnotes 
Financial support. 
Aspects of this work were supported by grants from the Medical Research Council, UK 
[MR/J013269/1] and the Biotechnology and Biological Sciences Research Council, UK 
[BB/J003506/1] to E.P.K. and G.H., from the Wellcome Trust, UK [Value in People award] to 
J.D.L. and C.P.B., and from the United States Public Health Service – National Institute on 
Drug Abuse [RO1DA030074] to C.C. 
  
MOL #98293 
 
35 
 
Figure Legends 
Figure 1. Inhibition of MOPr desensitization by Compound 101 in rat LC neurons. 
Traces A, D, G and J show outward potassium currents recorded from rat LC neurons in 
response to a receptor saturating concentrations of methionine enkephalin (Met Enk, 30 
µM), DAMGO (10 µM), endomorphin-2 (10 µM) and morphine (morph, 30 µM).  The Met 
Enk, DAMGO and endomorphin-2 responses desensitized rapidly over the 10 min of agonist 
application. The desensitization induced by morphine was less than that produced by the 
other agonists and was measured after 15 min of morphine application. Agonist responses 
returned to baseline after wash out (Met Enk) or when naloxone (nalox, 1 µM) was applied.  
The middle column of traces (B, E, H, K) show currents induced by each agonist in slices 
exposed to Compound 101 (Cmpd101, 30 µM) for at least 15 min before and during the 
application of the opioid agonists.  C, F, I and L show pooled data for the percentage 
desensitization after 10 min of Met Enk, DAMGO or endomorphin-2 application and 15 min 
of morphine application from experiments such as those illustrated in the two columns of 
experimental traces. Cmpd101 significantly inhibited the desensitization of all four agonists 
(Met Enk: n=5 for all experiments; DAMGO: n=4 for all experiments; endomorphin-2: n=6 for 
all experiments; morphine: n=6 for all experiments) In all histograms * indicates p<0.05, 
ANOVA compared to the appropriate control). All scale bars 50 pA, 2 min. 
 
Figure 2. Effect of GRK3 knockout and Compound 101 on methionine enkephalin-
induced MOPr desensitization in mouse LC neurons. A, Representative potassium 
currents in response to a receptor saturating concentration of Methionine enkephalin (Met 
Enk, 30 µM) recorded from mouse LC neurons in slices taken from either wildtype (WT, 
upper) or GRK3 knockout (KO, lower) mouse brains.  B, Pooled data from experiments as 
illustrated in A. The desensitization induced by Met Enk over a 10 min application was not 
different in GRK3 KO mice compared to WT littermate controls (GRK3 WT, n=6; GRK3 KO, 
n=6, t-test, p>0.05).C, Representative potassium currents in response to Met Enk (30 µM) 
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recorded from LC neurons from slices taken from C57Bl/6J mice that were either untreated 
(upper) or pre-treated with Cmpd101 (30 µM) for at least 15 min prior to and during the 
application of Met Enk (lower).  D, Pooled data for the percentage desensitization over the 
10 min of opioid agonist application from experiments such as those illustrated in C. 
Cmpd101 (3 and 30  µM) significantly inhibited Met Enk-induced desensitization measured 
after 10 min of agonist application. (n=5 for each; * indicates p<0.05, ANOVA compared to 
control). All scale bars 15 pA, 2 min. 
 
Figure 3. Compound 101 reduced the depression of the maximum response to 
morphine produced by DAMGO-induced desensitization. A & B, Representative 
potassium current traces showing the amplitude of the maximum response to morphine 
(morph) compared to that of noradrenaline (NA, 100 µM) in the absence (A) or after 
induction of desensitization (B) induced by application of DAMGO (10 µM for 12 min). The 
opioid antagonist naloxone (nalox, 1 µM) was added after morphine to bring the response 
back to baseline prior to application of NA. C, Representative current trace from an 
experiment in which slices were exposed to Compound 101 (Cmpd101, 30 µM) for at least 
15 min before and during the application of the opioid agonists. D, Pooled data from 
experiments as illustrated in A, B & C. DAMGO-induced desensitization inhibited the 
maximum response to morphine. Cmpd101 concentration-dependently reversed the 
DAMGO-desensitization-induced decrease in the morphine response (n=4 for all 
experiments; * indicates p<0.05, ANOVA). All scale bars 60 pA, 2 min. 
 
Figure 4. Inhibition of DAMGO-induced MOPr phosphorylation and arrestin 
recruitment by compound 101.  A, HEK 293 cells stably expressing HA-tagged rat MOPr 
were pre-treated with Cmpd101 for 30 min prior to stimulation with DAMGO (10 µM for 5 
min). Agonist-induced phosphorylation was assessed by Western blot analysis using an 
MOL #98293 
 
37 
 
antibody targeting phospho-Ser375 (pS375).  Anti-HA and anti-tubulin antibodies confirmed 
equal loading of the gels.  B, Western blots as illustrated in A were quantified by 
densitometry and expressed as a percentage of the maximal phosphorylation in response to 
DAMGO (10 µM) in each experiment. Cmpd101 (30 µM) abolished DAMGO-induced MOPr 
phosphorylation at Ser375 (n=3; * indicates p<0.05, ANOVA compared to Control + DAMGO). 
No phosphorylation was seen under control conditions or with Cmpd101 alone (n=3). C, 
DAMGO-induced arrestin3 translocation to the receptor was measured using the DiscoveRx 
PathHunter assay. DAMGO (10 µM) application produced a robust recruitment of arrestin3 
to the receptor that was significantly inhibited in cells that were pre-treated with Cmpd101 
(30 µM) for 30 min (n=3, * indicates p<0.05, ANOVA). D, Internalization of HA-MOPrs 
expressed in HEK 293 cells assessed by ELISA using an anti-HA antibody to label surface 
receptors. DAMGO (10 µM) induced a time-dependent loss of surface receptors that was 
significantly inhibited by Cmpd101 (n=3-4, * indicates p<0.05, ANOVA compared to control). 
E, Confocal images of HA-MOPrs following incubation with anti-HA antibody and fluorescein-
tagged secondary antibody (green), counterstained with Hoechst 33258 nucleic acid stain 
(blue) following incubation with DAMGO (10 µM) and/or Cmpd101 (30 µM). Images are from 
one experiment repeated 3 times. Scale bar = 10 µM. 
 
Figure 5. Effect of Compound 101 on the phosphorylation of ERK1/2 and Elk-1. A, 
ERK1/2 activity in HEK 293 cells expressing HA-MOPrs was assessed by Western blot 
using an antibody targeting phospho-ERK1/2. DAMGO (10 µM) application for 5 min 
produced a robust phosphorylation of ERK1/2 both in control cells and cells that had been 
pre-treated with Cmpd101 for 30 min. Antibodies against total ERK1/2 and tubulin confirmed 
equal loading of the gels. B, Western blots as illustrated in A were quantified by 
densitometry and expressed as a percentage of the maximal ERK1/2 phosphorylation in 
response to DAMGO (10 µM) in each experiment. Cmpd101 did not affect DAMGO-induced 
ERK1/2 phosphorylation (p>0.05, ANOVA), but at the higher 30 µM concentration, Cmpd101 
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produced a modest but significant activation of ERK1/2 on its own (p<0.05, one-sample t-
test versus control). n=4 for each. C, Phosphorylation of the ERK1/2 substrate Elk-1 in 
response to DAMGO was assessed by Western blot using an antibody targeting pSer383 [of 
Elk-1].  Treatment of HA-MOPr cells with DAMGO (10 µM) for 5 min produced 
phosphorylation of Elk-1 which was unaffected by pre-treatment with Cmpd101 (30 µM) for 
30 min. In contrast, agonist dependent phosphorylation of both Elk-1 and ERK1/2 was 
significantly reduced following pre-treatment for 30 min with the MEK1 inhibitor PD98059 (10 
µM). Antibodies against total ERK1/2 and tubulin confirmed equal loading of the gels. D, 
Western blots of pELK-1 as shown in C were quantified by densitometry and expressed as a 
percentage of the maximal Elk-1 phosphorylation in response to DAMGO (10 µM) in each 
experiment. Cmpd101 did not reduce DAMGO-induced Elk-1 phosphorylation at a 
concentration of 30 µM. n=3. E, The ERK1/2 inhibitor, PD98085 (10 µM), reduced both 
DAMGO-induced pELK-1 and pERK1/2 activation to basal levels. Data as in C quantified by 
densitometry. * signifies p<0.05, one-sample t-test versus control. n=3. 
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Supplementary Data Table 1. 
Inhibition of protein kinases by Compound 101 
Cmpd101 was studied at a concentration of 1 µM. Results are given as the percentage 
of kinase activity in the absence of the inhibitor.  The screen was performed in duplicate 
and results are given as a mean value with standard deviation.   
Kinase 
% Activity 
Remaining St Dev 
PRK2 7 1 
MSK1 10 1 
SGK1 31 5 
S6K1 47 4 
RSK1 48 5 
ROCK 2 53 1 
PKD1 65 1 
CAMKKb 69 3 
BTK 72 1 
VEG-FR 79 5 
CHK2 79 4 
ERK2 81 3 
AMPK (hum) 82 14 
PKBa 83 3 
ERK1 83 2 
TBK1 84 7 
EPH-A2 85 6 
GSK3b 85 6 
MLK3 86 4 
HER4 86 23 
CK1δ 86 8 
MKK1 88 11 
MST2 89 8 
SmMLCK 89 5 
TTK 89 3 
LKB1 91 5 
SRPK1 91 11 
Aurora B 92 3 
MARK3 92 7 
RIPK2 93 10 
PDK1 93 5 
JNK1 93 5 
Lck 94 2 
JAK2 94 3 
PKA 95 2 
NEK6 95 6 
PKCa 96 3 
IRAK4 96 4 
CAMK1 101 13 
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PAK4 101 8 
p38a MAPK 101 7 
SYK 103 8 
IGF-1R 103 3 
HIPK2 103 13 
EF2K 103 15 
Src 104 12 
TrkA 106 7 
CK2 106 6 
PLK1 106 2 
PIM1 107 7 
DYRK1A 112 3 
TAK1 113 11 
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Supplementary Data Figure 1. 
 
Kinome tree highlighting the primary targets of Cmpd101.  Phylogenetic 
representation of the human kinome is annotated showing the primary targets of Cmpd 
101 as GRK2/3 (yellow circles) (Manning et al., 2002).  The additional kinases we 
identified that are inhibited by Cmpd 101 in vitro (1 µM) are also highlighted (red 
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circles).  Diameter is proportional to the activity remaining; large red circle 0-25%, 
medium 25-50% and small 50-70%.  Grey circles indicate kinases that were tested in 
the screen but whose remaining activity was >70%.  The tree indicates broad sampling 
from across the kinome.  The tree was generated using Kinome Render and the 
illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com).    
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Supplementary Data Figure 2. 
 
DAMGO-induced MOPr desensitization was unaffected by inhibition of off-target 
kinases inhibited by Compound 101.  
A, Representative potassium current traces from either untreated rat LC neurons or 
neurons pre-treated with GSK650394 (10 µM) and Y-27632 (50 µM) for at least 15 min 
prior to and during application of DAMGO (10 µM).  
B, Pooled data from experiments as illustrated in A. The combination of kinase 
inhibitors which inhibit SGK1 (GSK650394), PRK2 and ROCK2 (Y-27632) did not 
affect DAMGO-induced desensitization (n=4 for both, p>0.05, t-test,). All scale bars 60 
pA, 2 min.  
 
 
